Literature DB >> 9440543

Immunoglobulin E production in mice by means of contact sensitization with a simple chemical, hapten.

H Nagai1, A Matsuo, H Hiyama, N Inagaki, K Kawada.   

Abstract

Production of IgE caused by repeated topical application of 2,4-dinitrofluorobenzene (DNFB) to the ears of BALB/c mice was investigated. Ear thickness increased in proportion to the number of applications. Eczematous changes of the skin included marked infiltration of neutrophils, eosinophils, and monocytes and hypertrophy of the epidermis. Ear thickness due to inflammation reached a maximum 24 hours after the second, third, fourth, and fifth applications. The strong expression of interferon-gamma and IL-2 messenger RNA (mRNA) in the skin lesions indicated the participation of Th1 type helper T cells in the delayed-type hypersensitivity reaction. After the fifth application, the mice showed an immediate cutaneous reaction in addition to the delayed-type hypersensitivity reaction. The immediate reaction appeared within 1 hour of application. Hapten-specific IgE also was detected in serum from the mice, and the expression of germline and productive Cepsilon mRNA was detected in cervical lymph nodes, whereas productive Cepsilon mRNA was detected in the spleen. These results indicate that five topical applications of DNFB to the ear produce local eczematous dermatitis and increase serum hapten-specific IgE level in mice. Eczematous dermatitis is mainly caused by Th1 type T cells, and IgE production is mediated by Th2 type T cells in the cervical lymph nodes. In addition, IgE class switching occurs in the cervical nodes and IgE production occurs in both lymph nodes and spleen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9440543     DOI: 10.1016/s0091-6749(97)70003-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

1.  Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice.

Authors:  H Nagai; Y Ueda; T Ochi; Y Hirano; H Tanaka; N Inagaki; K Kawada
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  An Atopic Dermatitis-Like Mouse Model by Alternate Epicutaneous Application of Dinitrofluorobenzene and an Extract of Dermatophagoides Farinae.

Authors:  Shujing Feng; Wengying Liu; Sisi Deng; Guoxuan Song; Jie Zhou; Zhengni Zheng; Zhiqiang Song
Journal:  Front Med (Lausanne)       Date:  2022-06-15

Review 3.  Mast cells in atopic dermatitis.

Authors:  Toshiaki Kawakami; Tomoaki Ando; Miho Kimura; Bridget S Wilson; Yuko Kawakami
Journal:  Curr Opin Immunol       Date:  2009-10-14       Impact factor: 7.486

4.  Transgenic rat model of childhood-onset dermatitis by overexpressing telomerase reverse transcriptase (TERT).

Authors:  Ryosuke Kaneko; Atsuko Sato; Shun Hamada; Takeshi Yagi; Ichiro Ohsawa; Mamitaro Ohtsuki; Eiji Kobayashi; Masumi Hirabayashi; Takashi Murakami
Journal:  Transgenic Res       Date:  2016-02-17       Impact factor: 2.788

5.  Is pimecrolimus cream (1%) an appropriate therapeutic agent for the treatment of external ear atopic dermatitis?

Authors:  Güçlü Kaan Beriat; Sefik Halit Akmansu; Cem Doğan; Eren Taştan; Ferda Topal; Bizden Sabuncuoğlu
Journal:  Med Sci Monit       Date:  2012-04

6.  Inhibitory Effect of Nelumbo nucifera (Gaertn.) on the Development of Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice.

Authors:  Rajendra Karki; Myung-A Jung; Keuk-Jun Kim; Dong-Wook Kim
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-09       Impact factor: 2.629

7.  A Case of Recurrent Urticaria Due to Formaldehyde Release from Root-Canal Disinfectant.

Authors:  Ji Hoon Jang; Seung Hyun Park; Hang Jea Jang; Sung Geun Lee; Jin Han Park; Jae Won Jeong; Chan Sun Park
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

8.  Effect of DHU001, a Polyherbal Formula, on Dinitrofluorobenzene-induced Contact Dermatitis (Type I allergy).

Authors:  Hyeung-Sik Lee; Byung-Chang Lee; Sae-Kwang Ku
Journal:  Toxicol Res       Date:  2010-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.